Cochrane Review Group
Gynaecological, Neuro-oncology and Orphan Cancer
129 systematic reviews in Gynaecological, Neuro-oncology and Orphan Cancer ask 1,590 questions. 17.7% have no studies to answer them, 25.8% rest on very low certainty evidence and 25.5% reach moderate or high certainty.
Reviews
129
Questions
1,590
current versions
No studies
17.7%
Moderate or high
25.5%
No studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings 2: PLD alone vs other conventional chemotherapy Quality of life · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 2: PLD alone vs other conventional chemotherapy Overall severe adverse events (grade > 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 2 studies · 964 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Anaemia (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 5 studies · 1968 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 6 studies · 2184 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Neurological (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | 3 studies · 1222 participants | Very low |
Summary of findings 3: PLD with chemotherapy vs PLD alone Quality of life · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 4.01 [1, 16.01] | 2 studies · 1028 participants | Very low |
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Neurological (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | RR 0.38 [0.2, 0.74] | 4 studies · 1900 participants | Very low |
Summary of findings 2: PLD alone vs other conventional chemotherapy Progression‐free survival (PFS) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | HR 0.94 [0.85, 1.04] | 4 studies · 1803 participants | Very low |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Quality of life (QoL) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Hypertension grade ≥ 3 · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Reviews 129
Hyperbaric oxygen therapy for late radiation tissue injury
CochraneSoF table
7 questions
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
CochraneSoF table
21 questions
Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
CochraneSoF table
48 questions
Antidepressants for the treatment of depression in people with cancer
CochraneSoF table
9 questions
Interventions for weight reduction in obesity to improve survival in women with endometrial cancer
CochraneSoF table
7 questions
Exercise interventions for adults with cancer receiving radiation therapy alone
CochraneSoF table
7 questions
Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer
CochraneSoF table
9 questions
Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
CochraneSoF table
30 questions
Perioperative enhanced recovery programmes for women with gynaecological cancers
CochraneSoF table
8 questions
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer
CochraneSoF table
25 questions
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer
CochraneSoF table
21 questions
Interventions for the management of fatigue in adults with a primary brain tumour
CochraneSoF table
22 questions
Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer
CochraneSoF table
5 questions
Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma
CochraneSoF table
21 questions
Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers
CochraneSoF table
1 questions
Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer
CochraneSoF table
6 questions
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines
CochraneSoF table
20 questions
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery
CochraneSoF table
14 questions
Interventions targeted at women to encourage the uptake of cervical screening
CochraneSoF table
8 questions
Prophylactic antibiotics for preventing gram‐positive infections associated with long‐term central venous catheters in adults and children receiving treatment for cancer
CochraneSoF table
3 questions
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer
CochraneSoF table
7 questions
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation
CochraneSoF table
14 questions
Anticoagulation for the initial treatment of venous thromboembolism in people with cancer
CochraneSoF table
24 questions
Music interventions for improving psychological and physical outcomes in people with cancer
CochraneSoF table
14 questions
Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early‐stage cervical cancer
CochraneSoF table
14 questions